Our Medicines

We are a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. In 2016, we invested $4.9 billion in R&D, which included the discovery and development of new medicines.

Below is a list of our company's marketed products. Any linked documents and websites are intended only for U.S. residents 18 years or older, as the availability of medicines and the indications for which they are approved can vary with country and region. 

Report Side Effects or Product Quality Complaints

(toll free US only)

Report Side Effects or Product Quality Complaints about Legacy Celgene Products (ABRAXANE®, IDHIFA®, INREBIC®, ISTODAX®, POMALYST®, REBLOZYL®, REVLIMID®, THALOMID®, VIDAZA®)
 

Learn More

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)

Triangle Icon

AZACTAM® (aztreonam for injection, USP)

Triangle Icon

EVOTAZ® (atazanavir and cobicistat)

Triangle Icon

HYDREA® (hydroxyurea)

Triangle Icon

KENALOG®-10 (triamcinolone acetonide)

Triangle Icon

KENALOG® -40 (triamcinolone acetonide) and 
KENALOG® -80 (triamcinolone acetonide)

Triangle Icon

PRAVACHOL® (pravastatin sodium)

Triangle Icon

REBLOZYL® (luspatercept-aamt)

Triangle Icon

VIDAZA® (azacitidine)

Triangle Icon

ZEPOSIA® (ozanimod) 

Triangle Icon

Legacy Brands

ATRIPLA® (efavirenz/ emtricitabine/ tenofovir disoproxil fumarate)

Triangle Icon

ETOPOPHOS® (etoposide phosphate)

Triangle Icon

GLUCOPHAGE® (metformin hydrochloride) and 
GLUCOPHAGE® XR (metformin hydrochloride) EXTENDED RELEASE

Triangle Icon

Please click below to see the Full U.S. Prescribing Information, including Boxed WARNING and Medication Guide/Patient Information for: